8-Isoprostaglandin E2 acts on thromboxane A2 (TP) receptors in vivo, inducing vasoconstriction and platelet aggregation; it enhances receptor-activated NFκB ligand (RANKL)-dependent osteoclastogenic potential of bone marrow hematopoietic precursors via the cAMP pathway.